Natalia Lopez-Andres

List of Publications by Year
in descending order

74	2,779	212478 28	206121 51
papers	citations	h-index	g-index

76	76	76	4105
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial. Clinical Research in Cardiology, 2022, 111, 614-626.	1.5	8
2	Mineralocorticoid receptor in cardiovascular diseasesâ€"Clinical trials and mechanistic insights. British Journal of Pharmacology, 2022, 179, 3119-3134.	2.7	22
3	Neutrophil Gelatinase-Associated Lipocalin From Macrophages Plays a Critical Role in Renal Fibrosis Via the CCL5 (Chemokine Ligand 5)-Th2 Cells-IL4 (Interleukin 4) Pathway. Hypertension, 2022, 79, 352-364.	1.3	13
4	Sex-Differences in Aortic Stenosis: Mechanistic Insights and Clinical Implications. Frontiers in Cardiovascular Medicine, 2022, 9, 818371.	1.1	15
5	Sex-Related Signaling of Aldosterone/Mineralocorticoid Receptor Pathway in Calcific Aortic Stenosis. Hypertension, 2022, 79, 1724-1737.	1.3	8
6	Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury. International Journal of Molecular Sciences, 2022, 23, 6680.	1.8	2
7	The Mineralocorticoid Receptor Antagonist Eplerenone Suppresses Interstitial Fibrosis in Subcutaneous Adipose Tissue in Patients With Type 2 Diabetes. Diabetes, 2021, 70, 196-203.	0.3	6
8	Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models. Scientific Reports, 2021, 11, 2591.	1.6	11
9	Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease. International Journal of Molecular Sciences, 2021, 22, 2310.	1.8	6
10	Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein. Biomedicines, 2021, 9, 639.	1.4	20
11	Editorial: Kidney and Distant Organ Crosstalk in Health and Disease. Frontiers in Physiology, 2021, 12, 712535.	1.3	1
12	Relationship between soluble protein ST2 (sST2) levels and microvascular complications in a cohort of patients with type 1 diabetes. Endocrinologia, Diabetes Y NutriciÃ“n, 2021, , .	0.1	0
13	Novel Insights into the Role of the Mineralocorticoid Receptor in Human Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 11656.	1.8	3
14	Soluble St2 Induces Cardiac Fibroblast Activation and Collagen Synthesis via Neuropilin-1. Cells, 2020, 9, 1667.	1.8	16
15	Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve. International Journal of Molecular Sciences, 2020, 21, 5372.	1.8	10
16	The Interaction between Mitochondrial Oxidative Stress and Gut Microbiota in the Cardiometabolic Consequences in Diet-Induced Obese Rats. Antioxidants, 2020, 9, 640.	2.2	23
17	A New Role for the Aldosterone/Mineralocorticoid Receptor Pathway in the Development of Mitral Valve Prolapse. Circulation Research, 2020, 127, e80-e93.	2.0	17
18	A Role for MMP-10 (Matrix Metalloproteinase-10) in Calcific Aortic Valve Stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1370-1382.	1.1	36

#	Article	IF	Citations
19	(Letter to the Editor) Response to: protective role of peroxiredoxin-4 in heart failure. Clinical Science, 2020, 134, 73-74.	1.8	0
20	Abstract P231: Macrophage Neutrophil Gelatinase-associated Lipocalin Has A Critical Role In Aldosterone-induced Renal Fibrosis Via The Ccl5-il4 Pathway.. Hypertension, 2020, 76, .	1.3	0
21	Soluble ST2 promotes oxidative stress and inflammation in cardiac fibroblasts: an in vitro and in vivo study in aortic stenosis. Clinical Science, 2019, 133, 1537-1548.	1.8	25
22	Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition. Scientific Reports, 2019, 9, 9607.	1.6	35
23	Arterial Remodeling and Dysfunction in the ZSF1 Rat Model of Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e005596.	1.6	17
24	Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners. Cells, 2019, 8, 1082.	1.8	21
25	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	2.9	182
26	Therapeutic Delivery of miR-148a Suppresses Ventricular Dilation in Heart Failure. Molecular Therapy, 2019, 27, 584-599.	3.7	41
27	CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. Hypertension, 2019, 73, 602-611.	1.3	78
28	Galectin-3 as a novel biotarget in cardiovascular alterations associated to development of severe aortic stenosis. Anales Del Sistema Sanitario De Navarra, 2019, 42, 199-208.	0.2	7
29	Abstract 010: Neutrophil Gelatinase Associated Lipocalin From Immune Cells is Involved in Renal Damages Induced by Mineralocorticoid Excess. Hypertension, 2019, 74, .	1.3	0
30	Specific Activation of the Alternative Cardiac Promoter of Cacna1c by the Mineralocorticoid Receptor. Circulation Research, 2018, 122, e49-e61.	2.0	15
31	Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage. Clinical Science, 2018, 132, 1471-1485.	1.8	37
32	Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	28
33	Neutrophil Gelatinase-Associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. Journal of Molecular and Cellular Cardiology, 2018, 115, 32-38.	0.9	47
34	Aldosterone Impairs Mitochondrial Function in Human Cardiac Fibroblasts via A-Kinase Anchor Protein 12. Scientific Reports, 2018, 8, 6801.	1.6	22
35	A role for fumarate hydratase in mediating oxidative effects of galectin-3 in human cardiac fibroblasts. International Journal of Cardiology, 2018, 258, 217-223.	0.8	17
36	Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats. Journal of Hypertension, 2018, 36, 368-376.	0.3	34

#	Article	IF	Citations
37	Cardiac CaV1.2 Signature Induced by Mineralocorticoid in Vessels. Biophysical Journal, 2018, 114, 627a.	0.2	0
38	A role for galectin-3Âin the development of early molecular alterations in short-term aortic stenosis. Clinical Science, 2017, 131, 935-949.	1.8	19
39	Aldosterone Target NGAL (Neutrophil Gelatinaseâ€"Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFÎºB Pathway. Hypertension, 2017, 70, 1148-1156.	1.3	67
40	Increased galectin-3 levels are associated with abdominal aortic aneurysm progression and inhibition of galectin-3 decreases elastase-induced AAA development. Clinical Science, 2017, 131, 2707-2719.	1.8	20
41	Differential Proteomics Identifies Reticulocalbin-3 as a Novel Negative Mediator of Collagen Production in Human Cardiac Fibroblasts. Scientific Reports, 2017, 7, 12192.	1.6	29
42	Differential proteomics reveals S100-A11 as a key factor in aldosterone-induced collagen expression in human cardiac fibroblasts. Journal of Proteomics, 2017, 166, 93-100.	1.2	9
43	The role of oxidative stress in the crosstalk between leptin and mineralocorticoid receptor in the cardiac fibrosis associated with obesity. Scientific Reports, 2017, 7, 16802.	1.6	32
44	Beneficial Effects of Galectin-3 Blockade in Vascular and Aortic Valve Alterations in an Experimental Pressure Overload Model. International Journal of Molecular Sciences, 2017, 18, 1664.	1.8	19
45	Soluble ST2 Levels and Left Ventricular Structure and Function in Patients With Metabolic Syndrome. Annals of Laboratory Medicine, 2016, 36, 542-549.	1.2	12
46	Galectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal Damage. PLoS ONE, 2016, 11, e0166272.	1.1	43
47	Role for Galectinâ€3 in Calcific Aortic Valve Stenosis. Journal of the American Heart Association, 2016, 5, .	1.6	55
48	Galectin-3, Cardiac Function, and Fibrosis. American Journal of Pathology, 2016, 186, 2232-2234.	1.9	15
49	The lysyl oxidase inhibitor (Î²-aminopropionitrile) reduces leptin profibrotic effects and ameliorates cardiovascular remodeling in diet-induced obesity in rats. Journal of Molecular and Cellular Cardiology, 2016, 92, 96-104.	0.9	52
50	Galectin-3 inhibition prevents adipose tissue remodelling in obesity. International Journal of Obesity, 2016, 40, 1034-1038.	1.6	41
51	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. European Journal of Heart Failure, 2015, 17, 764-771.	2.9	109
52	Neutrophil Gelatinaseâ€"Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids. Hypertension, 2015, 66, 158-166.	1.3	75
53	Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. American Journal of Physiology - Renal Physiology, 2015, 308, F500-F509.	1.3	42
54	Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension. Hypertension, 2015, 66, 767-775.	1.3	129

#	Article	IF	Citations
55	Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation. Molecular and Cellular Endocrinology, 2015, 411, 20-27.	1.6	26
56	Galectin-3 Participates in Cardiovascular Remodeling Associated With Obesity. Hypertension, 2015, 66, 961-969.	1.3	68
57	The Impact of Galectin-3 Inhibition onÂAldosterone-Induced Cardiac and RenalÂInjuries. JACC: Heart Failure, 2015, 3, 59-67.	1.9	164
58	P484The inhibition of lysyl oxidase improves the cardiovascular remodeling associated with obesity in rats. Cardiovascular Research, 2014, 103, S88.4-S88.	1.8	0
59	The potential role of leptin in the vascular remodeling associated with obesity. International Journal of Obesity, 2014, 38, 1565-1572.	1.6	47
60	Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress. Journal of Hypertension, 2014, 32, 1104-1114.	0.3	107
61	Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 67-75.	1.1	312
62	Absence of Cardiotrophin 1 Is Associated With Decreased Age-Dependent Arterial Stiffness and Increased Longevity in Mice. Hypertension, 2013, 61, 120-129.	1.3	42
63	A Role for Soluble ST2 in Vascular Remodeling Associated with Obesity in Rats. PLoS ONE, 2013, 8, e79176.	1.1	37
64	Cardiotrophin 1 Is Involved in Cardiac, Vascular, and Renal Fibrosis and Dysfunction. Hypertension, 2012, 60, 563-573.	1.3	55
65	CARDIOTROPHIN-1: A NEW KEY MOLECULE IN VASCULAR FIBROSIS, ARTERIAL STIFFNESS AND SENESCENCE. Artery Research, 2012, 6, 202.	0.3	0
66	Association of galectinâ€3 and fibrosis markers with longâ€term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CAREâ€HF (Cardiac Resynchronization in Heart Failure) trial. European Journal of Heart Failure, 2012, 14, 74-81.	2.9	203
67	GALECTIN-3 IS A POTENTIAL MEDIATOR OF ALDOSTERONE EFFECTS IN VASCULAR REMODELING. Journal of Hypertension, 2011, 29, e377.	0.3	0
68	A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H2372-H2382.	1.5	56
69	Aldosterone and the cardiovascular system: a dangerous association. Hormone Molecular Biology and Clinical Investigation, 2010, 4, 539-48.	0.3	2
70	3.3 CARDIOTROPHIN-1 IS A DETERMINANT OF ARTERIAL STIFFNESS AND THICKNESS IN RODENTS. Artery Research, 2010, 4, 147.	0.3	0
71	Vascular effects of cardiotrophin-1: a role in hypertension?. Journal of Hypertension, 2010, 28, 1261-1272.	0.3	28
72	P1.52 REGULATION AND ACTIONS OF CARDIOTROPHIN-1 IN CULTURED RAT VASCULAR SMOOTH MUSCLE CELLS. Artery Research, 2008, 2, 104.	0.3	0

#	Article	IF	Citations
73	Aldosterone Induces Cardiotrophin-1 Expression in HL-1 Adult Cardiomyocytes. Endocrinology, 2008, 149, 4970-4978.	1.4	39
74	Aldosterone/Mineralocorticoid Receptor Downstream Targets as Novel Therapeutic Targets to Prevent Cardiovascular Remodeling. , 0, , .		2